A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - Aramis

Bayer AG0 个研究点目标入组 1,500 人开始时间: 2014年7月17日最近更新: 2021年7月26日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Bayer AG
入组人数: 1,500

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Male

入选标准

•1. Written informed consent (IC) obtained.
•2. Males aged = 18 years.
•3. Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
•4. CRPC is defined as 3 rising PSA levels after the nadir taken at least 1 week apart during ADT. If the patient has a history of antiandrogen use, the most recent PSA value must be obtained at least 4 weeks after antiandrogen withdrawal. See Section 6.1.1 of the Protocol for further details.
•5. Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dl]) on GnRH agonist or antagonist therapy or after bilateral orchiectomy. Patients who have not undergone bilateral orchiectomy must continue GnRH therapy during the study.
•6. PSADT of = 10 months and PSA > 2 ng/ml at screening.See Section 6.1.1 of the Protocol for further details.
•7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
•8. Blood counts at screening: haemoglobin = 9.0 g/dl, absolute neutrophil count = 1500/µl (1.5x10^9/l), platelet count = 100,000/µl (100x10^9/l ) (patient must not have received any growth factor or blood transfusion within 7 days of the haematology laboratory obtained at screening).
•9. Screening values of serum alanine aminotransferase (ALT) and aspartate transaminase (AST) = 2.5 x upper limit of normal (ULN), total bilirubin = 1.5 x ULN (except patients with a diagnosis of Gilbert’s disease), creatinine = 2.0 x ULN.
•10. Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for 3 months after the end of the study treatment.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 300
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1200

排除标准

•1. History of metastatic disease at any time or presence of detectable metastases by blinded central reading within 42 days prior to start of study treatment. Presence of pelvic lymph nodes < 2 cm in short axis below the aortic bifurcation is allowed. See Section 6.1.1 of the Protocol for further details.
•2. Symptomatic local-regional disease that requires medical intervention including moderate/severe urinary obstruction or hydronephrosis due to prostate cancer.
•3. Acute toxicities of prior treatments and procedures not resolved to grade <=1 or baseline before randomisation.
•4. Prior treatment with: second generation AR inhibitors such as enzalutamide, ARN-509, darolutamide, other investigational AR inhibitors,
•CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700 or
•oral ketoconazole longer than for 28 days.
•5. Use of estrogens or 5-a reductase inhibitors (finasteride, dutasteride) within 28 days before randomisation and AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) at least 28 days before screening.
•6. Prior chemotherapy or immunotherapy for prostate cancer, except adjuvant/neoadjuvant treatment completed > 2 years before randomisation.
•7. Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before randomisation.
•8. Radiation therapy (external beam radiation therapy [EBRT], brachytherapy, or radiopharmaceuticals) within 12 weeks before randomisation.
•9. Severe or uncontrolled concurrent disease, infection or co-morbidity that, in the opinion of the investigator, would make the patient inappropriate for enrolment.
•10. Treatment with an osteoclast-targeted therapy (bisphosphonate or denosumab) to prevent skeletal-related events within 12 weeks before randomisation. Patients receiving osteoclast-targeted therapy to prevent bone loss at a dose and schedule indicated for osteoporosis may continue treatment at the same dose and schedule.
•11. Known hypersensitivity to the study treatment or any of its ingredients.
•12. Major surgery within 28 days before randomisation.
•13. Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV.
•14. Uncontrolled hypertension as indicated by a systolic BP >=160 mmHg or diastolic BP >=100 mmHg at screening.
•15. Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which treatment has been completed >=5 years ago and from which the patient has been disease-free.
•16. Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
•17. Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
•18. Treatment with any investigational drug within 28 days before randomisation.
•19. Any condition that in the opinion of the investigator would impair the patients’ ability to comply with the study procedures.
•20. Unable to swallow study medications and comply with study requirements.

研究者

发起方

Bayer AG

相似试验

进行中（未招募）

1 期

A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERHigh-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer)MedDRA version: 21.1Level: LLTClassification code 10066489Term: Progression of prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-003820-36-PTBayer AG1,500

进行中（未招募）

1 期

A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERHigh-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormone refractory prostate cancer)MedDRA version: 21.1Level: LLTClassification code 10066489Term: Progression of prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-003820-36-GBBayer AG1,500

进行中（未招募）

1 期

EUCTR2013-003820-36-BGBayer AG1,500

已完成

不适用

A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF TICAGRELOR 90 MG TWICE DAILY ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (THEMIS)-E11 Non-insulin-dependent diabetes mellitusNon-insulin-dependent diabetes mellitusE11

PER-089-13ASTRAZENECA - PERU,173

进行中（未招募）

1 期

A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (ODM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERHigh-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer)MedDRA version: 20.0Level: LLTClassification code 10066489Term: Progression of prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-003820-36-CZBayer AG1,500